Compare APRE & WVVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APRE | WVVI |
|---|---|---|
| Founded | 2006 | 1983 |
| Country | United States | United States |
| Employees | 8 | 310 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 12.5M |
| IPO Year | 2019 | N/A |
| Metric | APRE | WVVI |
|---|---|---|
| Price | $0.88 | $2.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.10 | N/A |
| AVG Volume (30 Days) | ★ 448.0K | 2.0K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $2.49 |
| 52 Week High | $2.22 | $7.17 |
| Indicator | APRE | WVVI |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 52.51 |
| Support Level | $0.90 | $2.54 |
| Resistance Level | $0.98 | $2.80 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 56.18 | 47.54 |
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines. The grapes are harvested, fermented, and made into wine at the company's Turner winery, and the wines are sold principally under its Willamette Valley Vineyards label and also under the Griffin Creek, Tualatin Estate, Pambrun, Maison Bleue, Natoma, Metis, and Elton labels. It operates under two operating segments, direct sales and distributor sales. Direct sales include retail sales in its tasting room and remote sites, wine club sales, online sales, on-site events, kitchen and catering sales, and other sales made directly to the consumer without the use of an intermediary. Distributor sales include all sales through a third party where prices are given at a wholesale rate.